LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm Today
Yahoo · 30 de oct de 2026
LLY shares extended gains on bullish Wall Street action after the company raised its full-year 2026 outlook.
Eli Lilly and Company
LLY
Sí, existe CEDEAR de LLY en Argentina. Operás bajo el ticker LLY en BYMA, con ratio 56:1 respecto a la acción en NYSE. Ratios y calculadora Ver próximos dividendos.
Empresa subyacente
HealthcareDrug Manufacturers - General
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- País
- United States
- Empleados
- 50.000
- Sitio web
- lilly.com
Precio histórico
Últimos 235 días · 12/11/25 — 29/10/26
+50.19%
Cotización y datos
NYSERatio 56:1 · Subyacente LLY
CEDEAR (ARS)
Precio
$ 41.940
Var. %
+4,59%
Volumen operado
33.007
Subyacente (USD)
Precio LLY
US$ 1.416,00
Teórico (precio / ratio)
LLY ÷ 56
US$ 25,29
Dólar MEP (LLYD)
Dividendos
Yield y fechas del subyacente vía Yahoo Finance. Ver calendario de dividendos.
Yield (USD)
0,5 %
Frecuencia (estimada)
Trim.
Próxima ex-date
12/11
Próximo pago
09/12
Cobro estimado (anual)
Dividendo anual USD ÷ ratio 56
USD 0,12
Preguntas frecuentes
¿Existe CEDEAR de LLY en Argentina?
Sí, existe el CEDEAR de LLY (Eli Lilly and Company) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es LLY.
¿Cuál es el ticker del CEDEAR de Eli Lilly and Company?
El ticker del CEDEAR de Eli Lilly and Company en Argentina es LLY. La acción subyacente cotiza en NYSE con el símbolo LLY.
¿Cuál es el ratio del CEDEAR LLY?
El CEDEAR LLY tiene un ratio de 56:1. Eso significa que 56 CEDEARs equivalen a 1 acción de LLY.
¿Cuánto vale el CEDEAR LLY hoy?
El CEDEAR LLY cotiza hoy a $ 41.940 en pesos argentinos, con una variación diaria de +4,59%.
¿Cuánto vale la acción LLY en dólares?
CEDEARs similares
Otros CEDEARs de Salud.
Noticias
Eli Lilly Is Now Worth as Much as Warren Buffett's Berkshire Hathaway. Can the Rally Keep Going?
Yahoo · 30 de oct de 2026
Eli Lilly's business is heavily driven by one product, while Berkshire Hathaway is a diversified conglomerate.
Amazon earnings fall short amid tech sell-off, and Anthropic becomes SpaceX's top partner
Yahoo · 30 de oct de 2026
In this episode of Market Hang, Laffer Tengler Investments CEO and CIO Nancy Tengler and her panel of experts weigh in on the latest round of disappointing earn…